Connect with us

World

US, EU health care giants jump at China’s International Import Expo

Published

on

A child receives a vaccination shot at a hospital in Huaibei in China’s eastern Anhui province on July 26, 2018.

– | AFP | Getty Images

SHANGHAI – Some of the world’s largest medical and health care companies are stepping up their bets on the Chinese market, regardless of slowing economic growth and trade tensions.

At this week’s China International Import Expo in Shanghai, health care giants such as AstraZeneca, Boston Scientific, Eli Lilly and Thermo Fisher Scientific unveiled massive floor displays to promote their products in the Chinese market.

The companies are looking at China’s hundreds of millions of consumers and local talent. China spent $777 billion on health last year, a figure set to grow rapidly if the country is to match the level of developed nations’ spending on the industry, according to Export.gov, a website run by the the International Trade Administration (ITA) and U.S. Department of Commerce.

The Chinese government launched its first import expo last November in an effort to bill the country as a buyer, rather than manufacturer, of the world’s goods. While the European Union and American chambers of commerce in Shanghai said members did not necessarily benefit from participating in the first trade fair, official reports said the total number of American companies joining the second expo increased by 18.

There’s a lot of tension at the national and central levels … but at the end of the day it’s governors and mayors that are looking for investment and trade and exports from their states.

Matthew Margulies

vice president of China operations for the U.S.-China Business Council

This year, Massachusetts-based Thermo Fisher said it showed off some products to the Chinese or global market for the first time.

Meanwhile, UK-based AstraZeneca announced the establishment of new regional headquarters in Chengdu, Guangzhou and Hangzhou, in addition to Beijing. The company said it is expanding the role of its research and development center in Shanghai.

“The challenge we’re bringing is that our development team here in Shanghai, is no longer … in charge of products in China only. They will take the lead on global projects,” CEO Pascal Soriot said at a ceremony on Wednesday.

Those are just two of more than 300 medical and health care companies that exhibited at the second China International Import Expo, and they accounted for about a tenth of roughly 3,000 exhibitors, according to official data.

China’s Ministry of Commerce said that at this year’s expo, U.S. companies had the largest exhibition floor space of any country, at 47,500 square meters (11.7 acres).

The primary contingent of these U.S. participants was concentrated in the medical and health care industries, according to state media. Per official data, these included Merck‘s and AstraZeneca’s 800 square-meter displays (8,611 square feet).

Unequal market access a challenge

These international health care giants are trying to tap the Chinese market even as foreign companies complain of policies that favor domestic players.

Carlo D’Andrea, vice president at the EU Chamber of Commerce in China, cited one example in which a local Chinese government stipulated that hospitals must purchase a certain amount of medical devices from domestic companies.

“If China is to offer the highest quality product, they should pay attention to the need of the patients,” D’Andrea said in a phone interview Tuesday.

The chamber’s business confidence survey for 2019 found that 43% of respondents said market access restrictions or regulatory barriers resulted in missed business opportunities. For more than 10% of those affected, they said those barriers were worth more than a quarter of their annual revenue in China, according to the survey.

That unequal market access in China’s state-dominated environment is a major issue in ongoing trade tensions between Beijing and Washington. The dispute between the world’s two largest economies has persisted for more than a year, with each country levying tariffs on hundreds of billions of dollars’ worth of goods from the other.

Opportunities beneath the surface

But for businesses, many opportunities remain at a subnational level, said Matthew Margulies, vice president of China operations for the U.S.-China Business Council.

“There’s a lot of tension at the national and central levels … but at the end of the day, it’s governors and mayors that are looking for investment and trade and exports from their states,” he said. “At that level there’s a lot of optimism around the conference.”

When China lowers the market access barrier and gives the Europeans opportunity to invest, they take the opportunity to invest in the territory.

Carlo D’Andrea

EU Chamber of Commerce in China

Case in point: A Wisconsin association for the ginseng root — known for its health benefits — had a presence at the expo despite noting that trade with China was about a quarter of what it had been due to tariffs.

China’s Ministry of Finance said this week that, as was the case last year, some goods would be exempt from tariffs if purchased during the import expo.

On Thursday, China’s Ministry of Commerce also indicated that a “phase one” trade agreement with the U.S. would include a rollback of tariffs from both sides. Beijing in September also exempted cancer drugs and a total of 16 American products from tariffs for a year.

The EU Chamber’s D’Andrea noted that cosmetics and pharmaceuticals are two industries in which he is seeing increased investment, thanks partly to improved government policy.

“When China lowers the market access barrier and gives the Europeans opportunity to invest, they take the opportunity to invest in the territory,” he said.

For global pharmaceutical companies, China already contributes an average 8% in revenues for the top ten global multinational players, McKinsey said in a report in May.

Source link

World

EU grants conditional clearance to Covid-19 antiviral remdesivir

Published

on

An employee of Egyptian pharmaceutical company Eva Pharma works on the production line of Remdesivir, a broad-spectrum antiviral medication which has been approved as a specific treatment for Covid-19.

Fadel Dawood | picture alliance via Getty Images

The European Commission said on Friday it had given conditional approval for the use of COVID-19 antiviral remdesivir following an accelerated review process.

The EU executive said the drug, produced by Gilead Sciences Inc, was the first medicine authorized in the European Union for treating COVID-19 following a “rolling review” begun by the European Medicines Agency at the end of April.

The agency reviews data as they become available on a rolling basis, while development is still ongoing.

The Commission said on Wednesday it was in negotiations with Gilead to obtain doses of remdesivir for the 27 European Union countries.

However, that may prove difficult after the U.S. Department of Health and Human Services announced it had secured all of Gilead’s projected production for July and 90% of that for August and September.

Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial. It is believed to be most effective in treating COVID-19 patients earlier in the course of disease than other therapies like the steroid dexamethasone.

Still, because remdesivir is given intravenously over at least a five-day period it is generally being used on patients sick enough to require hospitalization.

Source link

Continue Reading

World

A factory is challenging perceptions

Published

on

From cars to tables and computers to radios, factories manufacture a host of products integral to modern life. In many cases these facilities can be energy intensive and, if we’re being honest, not very pleasing to look at.  

As concerns about sustainability and the environment mount, however, a number of firms are attempting to reduce the impact of their operations with factories and offices using clever design, interesting materials and renewable sources of energy.

Earlier this week, designs for a new furniture factory in Norway were released, with the firms involved in its development hoping it will be sustainable, aesthetically pleasing and technologically advanced.

Known as The Plus, the 6,500-meter-squared building will be located in Magnor, Norway and surrounded by trees, with the site also functioning as a 300-acre park.

The architecture practice involved with the project’s design is the Bjarke Ingels Group (BIG) and their client is Vestre, a Norwegian furniture manufacturer established in 1947.

Construction work is due to start in August and when finished, the facility will be home to a range of sustainable features. According to BIG — which has offices in Copenhagen, New York, Barcelona and London — the building’s façade will be formed of local timber, recycled reinforcement steel and low-carbon concrete, while 1,200 solar panels will be installed on its roof. Overall, it’s hoped that greenhouse gas emissions from The Plus will be 50% less compared to a conventional factory.

A dedicated website outlining the plans for the building states that more than 90% of water used in production will be recycled. It adds that the factory will use “self-learning industrial robots” and driverless electric trucks. The robots will, according to the site, be able to apply color coatings to products using artificial intelligence and “object recognition” technology.

The Plus is one of many sustainability-focused buildings currently in development. Drinks giant Diageo recently announced plans for a carbon-neutral whiskey distillery in Kentucky.

In a statement issued Monday, Diageo, which produces drinks including Johnnie Walker, Smirnoff and Guinness, listed a number of features that it hopes will boost the sustainability of the distillery and its operations.

These include: the facility running on 100% renewable electricity; the use of LED bulbs indoors to boost energy efficiency; and all vehicles operated there being electric.

Meanwhile, last week, Australian tech firm Atlassian unveiled plans to construct what it described as “the world’s tallest hybrid timber building.”

The design will incorporate timber and a façade of glass and steel that will also use solar panels and have “self-shade capabilities.” Plans are also in place for a staggered outdoor garden to be integrated into the structure.

 

Source link

Continue Reading

World

Trump in trouble over coronavirus, Black Lives Matter: Expert

Published

on

President Donald Trump’s response to the coronavirus crisis and widespread protests over racial injustice have landed him “in big trouble” ahead of November’s election, according to one politics expert.

Speaking to CNBC’s “Street Signs Europe” on Friday, Inderjeet Parmar, professor of International Politics at City University, said Trump had been given two political gifts — but had squandered both.

“The pandemic, deadly as it has turned out to be, was a chance for him to unite the country, to rise above the political factionalism, and effectively act as the president of the United States in a period of emergency,” Parmar said.

“He didn’t do it, and he’s in big trouble because of that … President Trump has made his bed, and I think in the end he’s going to pay a terrible price, and that price is already being paid by a very large number of American people, both in terms of their health, and also in terms of the economy.”

A spokesperson for the White House was not immediately available to comment when contacted by CNBC.

There have been more than 2.7 million confirmed cases of Covid-19 and 128,740 fatalities from the virus in the U.S., according to data compiled by Johns Hopkins University. The U.S. has recorded the highest number of infections and the most deaths due to the coronavirus in the world.

The nationwide protests sparked by the police killing of George Floyd had also seen Trump fail to offer “anything in regard to any kind of significant sympathy,” Parmar added.

“I think what he’s shown is when it comes to real emergencies, when you need real leadership, he actually doesn’t have any of that kind of quality,” he said. “He talks about the people but he doesn’t appear to know the people’s interests lie in their economic wellbeing and their physical and personal safety.”

Parmar claimed that Trump’s response to both crises would weigh heavily on his chances of reelection in November.

“Trump has done a great deal for candidate Biden, so Biden can almost sit in his armchair in his basement and reap the rewards of President Trump’s total indifference to such a large set of problems in the United States,” he said.

Meanwhile, Parmar noted that Biden had been reaching out across the Democratic party and to opponents he had in the primaries.

“He is actually building bridges or moving a bit further to the left, and he’s opened a space for the likes of Bernie Sanders and Elizabeth Warren and Cortez and others, and I think their voices are going to be stronger in that administration,” he predicted.

Because of this, however, Parmar acknowledged that financial markets could well have something to worry about, as a Biden presidency was likely to lead to a greater focus on social programs.

“The broad neo-liberal market-oriented consensus has been shaken by the responses of government to the pandemic,” he told CNBC. “But I think the underlying philosophy of the market, I don’t think that’s been defeated, I think it’s going to carry on. So I suspect a lot of people are still going to be very unhappy.”

CNBC’s latest Change Research survey showed that Trump had slumped against Biden in polls, with support for Biden surging in several key battleground states.

Analysts at the Economist Intelligence Unit said in a report last month that while the presidential election would be closely fought, “the odds have now shifted firmly in Mr. Biden’s favour.” The EIU cited several reasons for the shift in support, but researchers emphasized the importance of how Trump had handled the Covid-19 outbreak and Black Lives Matter protests.

In June, Eurasia Group’s Jonathan Lieber told CNBC’s “Street Signs Asia” that Trump was “on the wrong side” of public opinion polls when it came to the Black Lives Matter movement, which was starting to seriously hurt the president’s approval ratings in the run up to the elections.

Source link

Continue Reading

Trending